Twist Bioscience Corp TWST

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better. In fields such as health care, food/agriculture, industrial chemicals/materials and academic research, by using our products, our customers are developing ways to better lives and improve the sustainability of the planet. We believe Twist Bioscience is uniquely positioned to help accelerate their efforts and the faster our customers succeed, the better for all of us.

We have developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. We have miniaturized traditional chemical DNA synthesis reactions to write over 1,000,000 pieces of DNA (oligonucleotides) up to 500 bases through direct synthesis on each silicon chip, approximately the size of a large mobile phone, reducing by 99.8% the amount of chemicals we estimate would be used per gene as compared to plate-based synthesis. We have combined our silicon-based DNA writing technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create an integrated technology platform that enables us to achieve high levels of quality, precision, automation, and manufacturing throughput at a significantly lower cost and quicker than our competitors.

Last close 139.92 2026-10-23
Market cap $8.77B 2026-06-30 share count
52-week range 23.30 - 219.71

Valuation FY2025 figures against the last close

P/S23.3x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.30

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $376.6M$313.0M$245.1M$203.6M$132.3M$90.1M$54.4M$25.4M$10.8M—
Cost of revenue $185.6M$179.6M$155.4M$119.3M$80.6M$61.4M$47.4M$32.2M$24.0M—
Gross profit $191.0M$133.3M$89.7M$84.2M$51.7M$28.7M$7.0M-$6.8M-$13.3M—
R&D $80.3M$90.9M$106.9M$120.3M$69.1M$43.0M$35.7M$20.3M$19.2M—
SG&A $247.0M$218.4M$189.7M$212.9M$135.9M$103.3M$80.1M$43.5M$26.1M—
Total operating expenses $512.8M$533.8M$462.3M$438.3M$285.1M$230.2M$163.2M$96.0M$69.2M—
Operating income -$136.3M-$220.8M-$217.2M-$234.8M-$152.7M-$140.1M-$108.8M-$70.6M-$58.5M—
Interest expense —$29.0K$5.0K$80.0K$367.0K$787.0K$1.3M$1.3M$905.0K—
Pre-tax income -$77.0M-$208.2M-$203.5M-$228.3M-$154.0M-$139.5M-$107.4M-$71.0M-$59.0M—
Income tax $719.0K$560.0K$1.2M$10.4M$1.9M$382.0K$292.0K$242.0K$280.0K—
Net income -$77.7M-$208.7M-$204.6M-$217.9M-$152.1M-$139.9M-$107.7M-$71.2M-$59.3M—
EPS, basic -1.30-3.60-3.60-4.04-3.15-3.57————
EPS, diluted -1.30-3.60-3.60-4.04-3.15-3.57-3.92-25.51-24.49—
Shares, diluted (wtd. avg.) 59.8M58.0M56.9M53.9M48.3M39.2M————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $183.0M$226.3M$289.3M$380.3M$467.4M$94.2M$47.4M$81.5M$31.6M$29.1M
Short-term investments $49.4M$50.1M$49.9M$126.3M$12.0M$196.3M$91.4M———
Receivables $57.0M$34.9M$44.1M$40.3M$28.5M$26.4M$12.1M$5.4M——
Inventory $28.3M$24.1M$32.1M$39.3M$31.8M$12.3M$7.3M$6.0M——
Total current assets $333.0M$346.8M$424.3M$596.5M$546.5M$334.9M$160.1M$95.7M——
Property, plant and equipment $102.3M$102.5M$131.8M$139.4M$44.1M$25.5M$20.8M$12.3M——
Goodwill $82.2M$85.8M$85.8M$85.8M$22.4M$1.1M$1.1M$1.1M——
Other intangibles $13.4M$14.5M$54.5M$59.7M$18.3M$307.0K$508.0K$712.0K——
Total assets $641.9M$614.3M$776.4M$961.4M$702.1M$398.9M$187.0M$115.8M——
Accounts payable $11.1M$1.6M$14.1M$20.1M$14.9M$4.8M$9.8M$7.5M——
Short-term debt ———$0$1.6M$3.3M$3.3M$2.5M——
Total current liabilities $91.4M$71.0M$73.3M$90.7M$63.1M$36.0M$30.4M$18.5M——
Long-term debt —————$1.4M$4.4M$7.2M——
Total liabilities $168.9M$141.6M$153.0M$172.0M$121.3M$62.6M$34.9M$26.7M——
Retained earnings -$1.32B-$1.24B-$1.03B-$828.4M-$610.6M-$458.5M-$318.5M-$210.9M——
Total equity $473.0M$472.7M$623.4M$789.4M$580.8M$336.3M$152.1M-$201.4M-$133.4M-$76.6M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$47.6M-$64.1M-$142.5M-$124.4M-$112.2M-$142.3M-$87.9M-$66.2M-$51.3M—
Depreciation and amortisation $24.9M$31.4M$29.3M$16.5M$9.8M$6.7M$6.1M$5.7M$5.0M—
Stock-based compensation $64.5M$50.9M$30.3M$79.7M$37.0M$17.1M$11.2M$3.0M$1.9M—
Capital expenditure $28.0M$5.1M$27.8M$101.9M$27.1M$9.9M$14.8M$3.7M$6.6M—
Investing cash flow -$24.8M-$3.1M$50.6M-$232.9M$156.2M-$114.7M-$104.8M$27.3M-$10.0M—
Financing cash flow $28.5M$6.9M$911.0K$270.5M$329.2M$303.7M$158.6M$88.8M$63.8M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001581280-25-000025.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -400M -200M 0 200M 400M Revenue, FY2017: 10.8M Gross profit, FY2017: -13.3M Net income, FY2017: -59.3M Revenue, FY2018: 25.4M Gross profit, FY2018: -6.8M Net income, FY2018: -71.2M Revenue, FY2019: 54.4M Gross profit, FY2019: 7M Net income, FY2019: -107.7M Revenue, FY2020: 90.1M Gross profit, FY2020: 28.7M Net income, FY2020: -139.9M Revenue, FY2021: 132.3M Gross profit, FY2021: 51.7M Net income, FY2021: -152.1M Revenue, FY2022: 203.6M Gross profit, FY2022: 84.2M Net income, FY2022: -217.9M Revenue, FY2023: 245.1M Gross profit, FY2023: 89.7M Net income, FY2023: -204.6M Revenue, FY2024: 313M Gross profit, FY2024: 133.3M Net income, FY2024: -208.7M Revenue, FY2025: 376.6M Gross profit, FY2025: 191M Net income, FY2025: -77.7M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $10.8M $25.4M $54.4M $90.1M $132.3M $203.6M $245.1M $313.0M $376.6M
Gross profit — -$13.3M -$6.8M $7.0M $28.7M $51.7M $84.2M $89.7M $133.3M $191.0M
Net income — -$59.3M -$71.2M -$107.7M -$139.9M -$152.1M -$217.9M -$204.6M -$208.7M -$77.7M

Recent filings and events

  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Regulation FD disclosure Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Results announced Item 2.02
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Other event Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%